Results 171 to 180 of about 4,821 (183)

Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment

Journal of Medicinal Chemistry
Leilei Zong, Zhoudong Zhang, Xionghao Li, Jie Jia, Xiaohui Jiang, Zitong Wang, Wenlang Liu, Xinyi Shen, Xiangyang Feng, Yangqing Huang, Haifeng Ding, Yunsong Song, Zheng Zheng, Jiandong Yuan, Huanqiu Li   +14 more
openaire   +1 more source

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Lancet, The, 2006
Daniel J Drucker, Michael A Nauck
exaly  

Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes

British Journal of Pharmacology, 2012
Debbie L Hay
exaly  

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Lancet, The
Ania M Jastreboff
exaly  

Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss

Nature Reviews Endocrinology
openaire   +1 more source

Amylin receptor agonists: A novel pharmacological approach in the management of diabetes mellitus

2001
Nyholm, B., Brock, B., Ørskov, L., Schmitz, O.   +3 more
openaire   +1 more source

Development of a Novel Assay for Direct Assessment of Selective Amylin Receptor Activation Reveals Novel Differences in Behavior of Selective and Nonselective Peptide Agonists

Molecular Pharmacology
Peter Keov, Denise Wootten, Patrick M. Sexton   +2 more
exaly  

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

Lancet, The, 2007
exaly  

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Lancet, The
exaly  

GLP-1 and amylin receptor multiagonism with amycretin for obesity management

Lancet, The
Bernard Ce Khoo, Tricia Tan
exaly